Chronic Myeloid Leukemia Coverage from Every Angle

Health-Related Quality-of-Life Outcomes With TKI Therapy in Newly Diagnosed CML

By: Sarah Campen, PharmD
Posted: Thursday, October 31, 2019

Patients with chronic myeloid leukemia (CML) who are treated with first-line dasatinib reported better health-related quality of life than those treated with first-line imatinib, according to the results of a multicenter case-control study published in Leukemia. “Our findings provide novel comparative [health-related quality-of-life] data that extend knowledge on the safety and efficacy of these two [tyrosine kinase inhibitors] and may help to facilitate first-line treatment decisions,” stated Fabio Efficace, PhD, of the Italian Group for Adult Hematologic Diseases, Rome, and colleagues.

Health-related quality of life was assessed in 323 newly diagnosed patients with CML receiving imatinib (n = 223) and dasatinib (n = 100). The European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire for CML (EORTC QLQ-CML24) was the primary scale for the comparative analysis.

Patients treated with dasatinib reported significantly higher disease-specific health-related quality-of-life outcomes in impact on daily life (P = .002), satisfaction with social life (P = .001), and symptom burden (P = .001). In patients 60 years of age and older, however, the differences favoring dasatinib were negligible across several cancer generic and disease-specific health-related quality-of-life categories.

Disclosure: For full disclosures of study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.